Of Humanized Mice and Men

who yearn to be gods.

You might want to start by reading https://www.bucksafa11.org/2019/08/26/you-might-not-think-slaverys-so-bad-now/

before moving on to

 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560170/

January 14 2013

Abstract

Antibody gene transfer, which involves the delivery of genes that encode potent, broadly neutralizing anti-HIV antibodies, is a promising new strategy to prevent HIV infection. A satellite symposium at the AIDS Vaccine 2012 conference brought together many of the groups working in this field. 

Despite nearly thirty years of intense study, efforts to develop a safe and effective HIV vaccine by conventional means have either failed or provided only modest, short-lived protection. While the tantalizing results of the HIV vaccine trial RV144 in Thailand continue to guide efforts to improve the efficacy and duration of a vaccine that harnesses the natural immune system, it remains uncertain when or if such efforts will succeed…

Antibody gene transfer is a novel protective strategy that bypasses the natural immune response, which has been the central focus of previous attempts to develop an HIV vaccine, by directing the production of antibodies from non-hematopoietic tissues, such as muscle (Figure 1). Because this approach skips many of the steps in the usual path of vaccine development, it has been described as a leapfrog strategy. Recent advances in the use of gene transfer for the correction of genetic deficiencies…,  …have bolstered the intriguing possibility of utilizing adeno-associated virus (AAV) vectors as a vehicle for antibody gene delivery in humans. Two recent studies have demonstrated the feasibility of this approach against both SIV in macaques as well as HIV in humanized mice

 

As the worldwide human antibody gene transfer experiments continue on, what they who are behind it fail to share with the public in their coercive propaganda programming is their decades old documented scientific history; a history that openly acknowledges bypassing the natural immune system results in complexities that turn their planned implanted nano-control knob into a long term T-1000 type detour. 

After learning that the results of two studies were reason enough for modern science poohbahs to abandon their previously established and rigorously defended method of ‘harnessing the natural immune system’, it occurred to me documentation of the results of efforts of the new vaxx technocrats might be a helpful clarification for the purposely misguided, thus enabling parity for the  UNdereducated public who are embracing the built in mediocrity of the ‘go along to get along’ philosophy the https://lasd.org/operation-homebound army of the mundane enforces; that is, a parity with the mask-less who had no problem detecting the grievous opprobrium of the weightless political stench  early on in this power grab.

Aug 01, 2001

https://www.cell.com/action/showPdf?pii=S1525-0016%2801%2990435-6

Gene replacement therapy represents an interesting new approach for the treatment of cystic fibrosis (CF) lung disease. Basic research suggests that CF gene therapy is feasible, but major technological
challenges must be addressed before clinical applications are likely to succeed…

 

Oct 3, 2002
https://www.nature.com/articles/3301791.pdf

Conclusion
Although topical gene transfer to the airways for CF gene therapy is more challenging than originally thought, significant progress has been made in pre-clinical research over the last 2 years to overcome some of the hurdles.

Most importantly, the identification of more effective viral and non-viral gene transfer agents for airway gene delivery, development of new delivery routes and most recently alternative strategies are keeping the development of CF gene therapy well on track.

Sept 29 2004

https://www.nature.com/articles/3302368.pdf  

Over the last decade, it became apparent that gene transfer to the AECs is difficult. This is perhaps unsurprising, given the lung has evolved to keep foreign particles out. The major obstacle for most viral GTAs is the effective immune surveillance mechanisms in the
lung, which prohibit repeat administration. Many strategies
to overcome this problem have already been
explored, but have not yet been successful. In our view,
this may be a difficult hurdle to overcome.

Non-viral gene transfer has traditionally been inefficient, but recently developed nanoparticles and ligand-targeting appear
to be overcoming this problem. Importantly, physical
delivery methods to increase non-viral gene transfer are
currently being assessed in the lung. Although gene
therapy for CF is not yet a clinical reality, the many
innovative strategies currently being assessed should
lead to efficient and repeatable airway gene transfer
within the next few years.

April 1 2014

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3996976/

James W Wilson :

At the turn of the century, the field of gene therapy saw a significant erosion of support for a variety of reasons (Wilson, ). Despite extensive clinical trial activity, the field had no clear demonstration of clinical success. My assessment was that available vector technology was not suitable for most of the clinical applications that were contemplated. I approached Tachi Yamada, who at the time was chief scientific officer of SmithKlineBeecham (SB), for advice about the current state of the field and what I could do to move it forward. Tachi was the chair of my department at Michigan and a very important mentor. He encouraged me to “go back to the bench” and focus on creating better vectors and offered to have SB help support this effort through a sizable sponsored research agreement with Penn. We had the financial support—we now needed a plan!

March 9 2015

https://www.nytimes.com/2015/03/10/health/protection-without-a-vaccine.html

It’s not a vaccine.

Aug 2016

https://investors.biogen.com/news-releases/news-release-details/biogen-announces-collaboration-university-pennsylvania-multiple

Biogen and UPenn join forces to commercialize gene therapies

January 31 2018

https://www.technologyreview.com/2018/01/31/3448/the-doctor-responsible-for-gene-therapys-greatest-setback-is-sounding-a-new-alarm/

The warning comes amidst a scramble by three companies—Sarepta Therapeutics, Pfizer, and Solid Biosciences—to be the first to use the technique to cure muscular dystrophy. That disease strikes young boys, destroys their muscles, and kills them by their 20s.

May 24 2019

https://www.pennmedicine.org/news/news-releases/2019/may/zolgensma-based-on-delivery-system-discovered-by-penn-gene-therapy-pioneer

 

Sept 12 2019

https://cen.acs.org/business/The-redemption-of-James-Wilson-gene-therapy-pioneer/97/i36

Squinto was astounded. “He runs his gene therapy center like you’d run a very efficient company,” he thought. With Wilson’s infrastructure and decades of know-how, any spin-off company financed by Squinto’s firm could hit the ground running. “It’s all here,” he told Wilson. “And I’m willing to pay for it.”

Over the next few months, the duo negotiated an intimate arrangement: they would form a new company, and Wilson’s lab at Penn would function as its R&D arm…

April 17 2020

https://www.washingtonpost.com/health/the-journey-from-scientific-breakthrough-to-a-life-changing-cystic-fibrosis-drug/2020/04/17/08e70a0c-0bda-11ea-bd9d-c628fd48b3a0_story.html

The importance of the cystic fibrosis gene discovery went far beyond a single illness. It helped build the case for the $3 billion project to sequence the entire human genome, which would alter understanding of human biology and shed light on rare and common diseases.

But the story of cystic fibrosis has been illustrative in a way that no one could have anticipated back then. In the early days of human genetics, the path seemed straightforward: Find the gene, fix the gene and repeat for other diseases. The cystic fibrosis journey, from an exuberant moment of insight to a major success, would take 30 years of persistent, methodical work: a feat of science, business, fundraising and patience that has become a model for other diseases.

https://www.cff.org/Research/Research-Into-the-Disease/Restore-CFTR-Function/Gene-Therapy-for-Cystic-Fibrosis/

Gene therapy has been around for quite a while now, a couple decades in some places. My point is, it’s not been a complete success so far. Anywhere. We are being hustled into accepting this covid-19   assault based on a ‘therapy’ that  has been mired in disappointment, distortion and disgrace for most of its existence. Who could ask for a better setting for the birth of a new world order?
Or a tool to assist its success?

2015 Jul 22

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632204/

Safety monitoring in the Vaccine Adverse Event Reporting System

 Abstract

The Centers for Disease Control and Prevention (CDC) and the U.S. Food and Drug Administration (FDA) conduct post-licensure vaccine safety monitoring using the Vaccine Adverse Event Reporting System (VAERS), a spontaneous (or passive) reporting system. This means that after a vaccine is approved, CDC and FDA continue to monitor safety while it is distributed in the marketplace for use by collecting and analyzing spontaneous reports of adverse events that occur in persons following vaccination…

Generally, VAERS data cannot be used to determine if a vaccine caused an adverse event. VAERS data interpreted alone or out of context can lead to erroneous conclusions about cause and effect as well as the risk of adverse events occurring following vaccination. CDC makes VAERS data available to the public and readily accessible online…

Introduction

CDC and FDA co-administer the Vaccine Adverse Event Reporting System (VAERS), a spontaneous (or passive) reporting system []. Spontaneous surveillance means that no active effort is made to search for, identify and collect information, but rather information is passively received from those who choose to voluntarily report their experience. Therefore, VAERS relies on the intuition and experience of healthcare professionals in particular, but likewise for patients, parents and caregivers, to recognize and report unusual or unexpected events following vaccination or suspected vaccine safety problems. CDC and FDA also independently administer large-linked electronic health record-based surveillance systems [,]. Various methods and statistical techniques are used to analyze VAERS data, which CDC and FDA use to guide further safety evaluations and inform decisions around vaccinerecommendations and regulatory action.

Furthermore, VAERS transmits its vaccine adverse event reports to the Uppsala Monitoring Center, the World Health Organization collaborating center for international drug and vaccine safety monitoring [,], in order to contribute to the global pharmacovigilance effort along with other countries that employ passive vaccine safety monitoring systems. VAERS data must be interpreted with caution due to the inherent limitations of passive surveillance. VAERS is primarily a safety signal detection and hypothesis generating system…

Which brings US to this story…

and now this story… https://principia-scientific.com/laboratories-in-us-cant-find-covid-19-in-1500-positive-tests/

Do you really think, based on the amount of information provided above, ‘medical/scientific’ protocol has ever been followed in this covert covid war?

With all this scientific background fresh in your mind along with the awareness of the role computer monitoring systems played in the stolen election  consider a couple of questions based on the following video presentation?

Do you think the John Malkovich characterization of Lennie Small is a fair representation of Nancy Pelosi’s alleged stated opinion of American citizens level of mental acuity?

If you do, who or what do you think Gary Sinese characterization of George Milton would represent in this war they publicly declared on covid that actually targets US?

Democrats, Republicans, independents, bureaucrats?

Or those further up the chain?

You getting the picture yet?

What do you think?

 

Leave a Reply

Your email address will not be published. Required fields are marked *

This Blog Makes Frequent Trips to the Border